Wedbush Begins Coverage on Zura Bio (NASDAQ:ZURA)

Analysts at Wedbush started coverage on shares of Zura Bio (NASDAQ:ZURA) in a note issued to investors on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $15.00 price target on the stock. Wedbush’s price target indicates a potential upside of 132.92% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. Wall Street Zen cut shares of Zura Bio from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Leerink Partners raised Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.60.

Zura Bio Stock Up 2.7%

Shares of Zura Bio stock opened at $6.44 on Monday. Zura Bio has a 12-month low of $0.97 and a 12-month high of $6.88. The stock has a market capitalization of $418.73 million, a P/E ratio of -9.91 and a beta of 0.21. The company has a 50-day simple moving average of $5.06 and a 200 day simple moving average of $3.63.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). On average, equities analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. raised its position in shares of Zura Bio by 165.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 216,810 shares of the company’s stock worth $1,136,000 after purchasing an additional 135,087 shares during the period. Allworth Financial LP bought a new stake in Zura Bio during the 4th quarter worth approximately $30,000. UBS Group AG increased its stake in Zura Bio by 54.1% during the 4th quarter. UBS Group AG now owns 470,540 shares of the company’s stock worth $2,466,000 after purchasing an additional 165,211 shares in the last quarter. Armistice Capital LLC raised its holdings in Zura Bio by 1.6% during the 3rd quarter. Armistice Capital LLC now owns 1,560,000 shares of the company’s stock worth $6,755,000 after buying an additional 24,000 shares during the period. Finally, Scientech Research LLC bought a new position in Zura Bio in the third quarter valued at approximately $45,000. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.